Vincent Castonguay

Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

Can Urol Assoc J, 17 (5), 2023.

Résumé | Liens:

Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol, 24 (4), 2023.

Résumé | Liens:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Cancer Lett, 553 , 2023.

Résumé | Liens:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Bjarnason GA, Breau RH, Pouliot F, Swaminath, A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Adv Radiat Oncol, 7 (4), 2022.

| Liens:

Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

J Immunother Cancer, 10 (11), 2022.

Résumé | Liens:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Kollmannsberger C, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Graham J, Bjarnason GA, Breau RH, Pouliot F, Swaminath A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Adv Radiat Oncol, 7 (4), 2022.

Résumé | Liens:

Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, Patenaude F, Breau RH, Pouliot F, Kapoor A, Wood LA

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Clin Genitourin Cancer, 20 (3), 2022.

Résumé | Liens:

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, Gumus M, Olivera Hurtado de Mendoza M, Samouelian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ,

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Obstet Gynecol Surv, 77 (1), 2022.

| Liens:

Zhang H, Basappa NS, Ghosh S, Joy I, Lalani AKA, Hansen AR, Heng DYC, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Kapoor A, Graham J

Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)

Kidney Cancer, 5 (1), 2021.

| Liens:

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Olivera Hurtado de Mendoza M, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ,

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

N Engl J Med, 385 (20), 2021.

Résumé | Liens: